A Randomized, Double-blind, Placebo-controlled Pilot Study to Assess the Safety and Efficacy of Ifetroban for the Treatment of Portal Hypertension in Cirrhotic Patients
Latest Information Update: 21 Jan 2022
At a glance
- Drugs Ifetroban (Primary) ; Ifetroban (Primary)
- Indications Portal hypertension
- Focus Adverse reactions
- Sponsors Cumberland Pharmaceuticals
- 26 Feb 2019 Results published in the Media Release
- 15 Aug 2018 Status changed from active, no longer recruiting to completed.
- 12 Jul 2018 Status changed from recruiting to active, no longer recruiting.